{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:42:17Z","timestamp":1781545337134,"version":"3.54.5"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Harv Rev Psychiatry"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This revision of previous algorithms for the pharmacotherapy of generalized anxiety disorder was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. Algorithms from 1999 and 2010 and associated references were reevaluated. Newer studies and reviews published from 2008\u201314 were obtained from PubMed and analyzed with a focus on their potential to justify changes in the recommendations. Exceptions to the main algorithm for special patient populations, such as women of childbearing potential, pregnant women, the elderly, and those with common medical and psychiatric comorbidities, were considered. Selective serotonin reuptake inhibitors (SSRIs) are still the basic first-line medication. Early alternatives include duloxetine, buspirone, hydroxyzine, pregabalin, or bupropion, in that order. If response is inadequate, then the second recommendation is to try a different SSRI. Additional alternatives now include benzodiazepines, venlafaxine, kava, and agomelatine. If the response to the second SSRI is unsatisfactory, then the recommendation is to try a serotonin-norepinephrine reuptake inhibitor (SNRI). Other alternatives to SSRIs and SNRIs for treatment-resistant or treatment-intolerant patients include tricyclic antidepressants, second-generation antipsychotics, and valproate. This revision of the GAD algorithm responds to issues raised by new treatments under development (such as pregabalin) and organizes the evidence systematically for practical clinical application.<\/jats:p>","DOI":"10.1097\/hrp.0000000000000098","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T16:23:37Z","timestamp":1467822217000},"page":"243-256","source":"Crossref","is-referenced-by-count":21,"title":["The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder"],"prefix":"10.1097","volume":"24","author":[{"given":"Harmony Raylen","family":"Abejuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Osser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230816","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1475-2891-9-42","article-title":"Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review","volume":"9","year":"2010","journal-title":"Nutr J"},{"key":"bib2-20230816","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1517\/14656566.2011.618496","article-title":"Pharmacological treatment of generalized anxiety disorder","volume":"12","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"bib3-20230816","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145710001434","article-title":"Evidence-based pharmacological treatment of generalized anxiety disorder","volume":"14","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"bib5-20230816","article-title":"Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines","volume":"13","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"bib6-20230816","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.clinthera.2009.06.004","article-title":"Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder","volume":"31","year":"2009","journal-title":"Clin Ther"},{"issue":"suppl 2","key":"bib7-20230816","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4088\/JCP.s.7002.06","article-title":"Refractory generalized anxiety disorder","volume":"70","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"suppl 11","key":"bib8-20230816","first-page":"15","article-title":"Generalized anxiety disorder: nature and course","volume":"62","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bib9-20230816","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3928\/0048-5713-19990501-10","article-title":"Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence","volume":"29","year":"1999","journal-title":"Psychiatr Ann"},{"key":"bib10-20230816","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881108096505","article-title":"A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)","volume":"24","year":"2010","journal-title":"J Psychopharmacol"},{"key":"bib11-20230816","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15622970601110273","article-title":"Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders","volume":"8","year":"2007","journal-title":"World J Biol Psychiatry"},{"key":"bib12-20230816","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0193-953X(05)70204-5","article-title":"The epidemiology of generalized anxiety disorder","volume":"24","year":"2001","journal-title":"Psychiatr Clin North Am"},{"key":"bib13-20230816","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1089\/acm.2009.0066","article-title":"Kava and St. John\u2019s Wort: current evidence for use in mood and anxiety disorders","volume":"15","year":"2009","journal-title":"J Altern Complement Med"},{"key":"bib14-20230816","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0b013e318291be67","article-title":"Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study","volume":"33","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"bib15-20230816","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/acm.2007.7117","article-title":"A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD)","volume":"14","year":"2008","journal-title":"J Altern Complement Med"},{"key":"bib16-20230816","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/JCP.0b013e3181ac935c","article-title":"A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder","volume":"29","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"bib17-20230816","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"28","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"bib18-20230816","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/JCP.0b013e318224864d","article-title":"A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder","volume":"31","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"bib19-20230816","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/10673229.2011.614483","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder","volume":"19","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"bib20-20230816","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10673220802277904","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression","volume":"16","year":"2008","journal-title":"Harv Rev Psychiatry"},{"key":"bib21-20230816","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/10673220903523524","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on bipolar depression","volume":"18","year":"2010","journal-title":"Harv Rev Psychiatry"},{"key":"bib22-20230816","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"bib23-20230816","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/HRP.0000000000000018","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an algorithm for acute mania","volume":"22","year":"2014","journal-title":"Harv Rev Psychiatry"},{"key":"bib24-20230816","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.IDT.0000391328.04097.1e","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program","volume":"45","year":"2010","journal-title":"Psychopharm Rev"},{"key":"bib26-20230816","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1176\/ajp.151.9.1272","article-title":"The empirical basis of generalized anxiety disorder","volume":"151","year":"1994","journal-title":"Am J Psychiatry"},{"key":"bib28-20230816","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","year":"2004","journal-title":"Am J Psychiatry"},{"key":"bib29-20230816","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1017\/S1461145712000922","article-title":"Effects of pregabalin on sleep in generalized anxiety disorder","volume":"16","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"bib30-20230816","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.sleep.2003.06.006","article-title":"The effects of trazodone on sleep in patients treated with stimulant antidepressants","volume":"5","year":"2004","journal-title":"Sleep Med"},{"key":"bib31-20230816","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1176\/ajp.151.7.1069","article-title":"Trazodone for antidepressant-associated insomnia","volume":"151","year":"1994","journal-title":"Am J Psychiatry"},{"key":"bib32-20230816","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/archpsyc.65.5.551","article-title":"Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder","volume":"65","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"bib33-20230816","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/sleep\/30.8.959","article-title":"Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations","volume":"30","year":"2007","journal-title":"Sleep"},{"key":"bib34-20230816","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.JGP.0000196629.19634.00","article-title":"A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults","volume":"14","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"bib35-20230816","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2008.977","article-title":"Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial","volume":"301","year":"2009","journal-title":"JAMA"},{"key":"bib36-20230816","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1440-1819.2009.02055.x","article-title":"Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder","volume":"64","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"bib37-20230816","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1532-5415.2002.50003.x","article-title":"Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials","volume":"50","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"bib38-20230816","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/01.JGP.0000204328.50105.b3","article-title":"Cardiovascular changes associated with venlafaxine in the treatment of late-life depression","volume":"14","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"bib39-20230816","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1192\/bjp.bp.107.037788","article-title":"Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder","volume":"193","year":"2008","journal-title":"Br J Psychiatry"},{"key":"bib40-20230816","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JGP.0b013e31815aff5c","article-title":"Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study","volume":"16","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"bib41-20230816","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/2045125313510194","article-title":"Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports","volume":"4","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"bib42-20230816","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijcp.12182","article-title":"Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment","volume":"68","year":"2014","journal-title":"Int J Clin Pract"},{"key":"bib43-20230816","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/JCP.0b013e3182197055","article-title":"Are hypnotic benzodiazepine receptor agonists teratogenic in humans?","volume":"31","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"bib44-20230816","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1176\/appi.ajp.2007.06071172","article-title":"Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth","volume":"164","year":"2007","journal-title":"Am J Psychiatry"},{"key":"bib45-20230816","doi-asserted-by":"crossref","first-page":"f4877","DOI":"10.1136\/bmj.f4877","article-title":"Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States","volume":"347","year":"2013","journal-title":"BMJ"},{"key":"bib46-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/h0080151","article-title":"The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization","volume":"66","year":"1996","journal-title":"Am J Orthopsychiatry"},{"key":"bib48-20230816","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","year":"2008","journal-title":"Am J Psychiatry"},{"key":"bib49-20230816","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.163.2.232","article-title":"Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers","volume":"163","year":"2006","journal-title":"Am J Psychiatry"},{"key":"bib50-20230816","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","year":"2013","journal-title":"Am J Psychiatry"},{"key":"bib51-20230816","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4088\/JCP.14ac09649","article-title":"Bipolar therapeutics update 2014: a tale of 3 treatments","volume":"76","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"bib52-20230816","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.13m08847","article-title":"Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial","volume":"75","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"suppl 1","key":"bib53-20230816","first-page":"8","article-title":"Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders","volume":"67","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"bib54-20230816","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","article-title":"Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study","volume":"23","year":"2008","journal-title":"Eur Psychiatry"},{"key":"bib55-20230816","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":"Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study","volume":"13","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"bib56-20230816","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"bib57-20230816","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan","volume":"170","year":"2013","journal-title":"Am J Psychiatry"},{"key":"bib60-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.ajp.2013.13070905","article-title":"Cardiac safety concerns remain for citalopram at dosages above 40 mg\/day","volume":"171","year":"2014","journal-title":"Am J Psychiatry"},{"key":"bib61-20230816","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.2013.13081052","article-title":"Safety of high-dosage citalopram","volume":"171","year":"2014","journal-title":"Am J Psychiatry"},{"key":"bib62-20230816","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.v61n1109","article-title":"Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment","volume":"61","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"bib64-20230816","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4088\/JCP.v65n1011","article-title":"Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"bib65-20230816","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"bib66-20230816","first-page":"h3190","article-title":"Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports","volume":"351","year":"2015","journal-title":"BMJ"},{"key":"bib67-20230816","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder","volume":"21","year":"2007","journal-title":"J Psychopharmacol"},{"key":"bib68-20230816","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","year":"2006","journal-title":"Br J Psychiatry"},{"key":"bib69-20230816","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/(SICI)1099-1166(1998100)13:10<717::AID-GPS857>3.0.CO;2-M","article-title":"Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam","volume":"13","year":"1998","journal-title":"Int J Geriatr Psychiatry"},{"key":"bib70-20230816","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","year":"2011","journal-title":"BMJ"},{"key":"bib71-20230816","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hup.1019","article-title":"How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database","volume":"24","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"bib72-20230816","first-page":"16","article-title":"Real-world data on SSRI antidepressant side effects","volume":"6","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"bib73-20230816","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archpsyc.65.7.795","article-title":"Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents","volume":"65","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"bib74-20230816","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/appi.ajp.2013.12111467","article-title":"Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding","volume":"171","year":"2014","journal-title":"Am J Psychiatry"},{"key":"bib75-20230816","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","article-title":"Effect of selective serotonin reuptake inhibitors on the risk of fracture","volume":"167","year":"2007","journal-title":"Arch Intern Med"},{"key":"bib76-20230816","doi-asserted-by":"crossref","first-page":"b2880","DOI":"10.1136\/bmj.b2880","article-title":"Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration","volume":"339","year":"2009","journal-title":"BMJ"},{"key":"bib77-20230816","first-page":"400","article-title":"[Efficacy and tolerability of escitalopram in anxiety disorders: a review]","volume":"34","year":"2008","journal-title":"Encephale"},{"key":"bib78-20230816","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0269881113492027","article-title":"A review of the adverse effects and safety of noradrenergic antidepressants","volume":"27","year":"2013","journal-title":"J Psychopharmacol"},{"key":"bib79-20230816","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v66n0603","article-title":"Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder","volume":"66","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"bib80-20230816","first-page":"929","article-title":"The role of duloxetine in the treatment of anxiety disorders","volume":"4","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"bib81-20230816","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/S1092852900021544","article-title":"Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER","volume":"12","year":"2007","journal-title":"CNS Spectr"},{"key":"bib82-20230816","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/archgenpsychiatry.2010.170","article-title":"Time to relapse after 6 and 12 months\u2019 treatment of generalized anxiety disorder with venlafaxine extended release","volume":"67","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"bib83-20230816","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/msj.20041","article-title":"Anxiety disorders: a comprehensive review of pharmacotherapies","volume":"75","year":"2008","journal-title":"Mt Sinai J Med"},{"key":"bib84-20230816","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00023210-200923060-00006","article-title":"Duloxetine: a review of its use in the treatment of generalized anxiety disorder","volume":"23","year":"2009","journal-title":"CNS Drugs"},{"key":"bib85-20230816","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000110055","article-title":"Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis","volume":"77","year":"2008","journal-title":"Psychother Psychosom"},{"key":"bib86-20230816","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000118837","article-title":"Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies","volume":"25","year":"1992","journal-title":"Neuropsychobiology"},{"key":"bib87-20230816","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.1994.03950090052008","article-title":"Buspirone treatment of anxious alcoholics. A placebo-controlled trial","volume":"51","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"bib88-20230816","first-page":"300","article-title":"The diagnosis and treatment of generalized anxiety disorder","volume":"110","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"bib89-20230816","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"bib90-20230816","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hup.470100303","article-title":"A multicenter, double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety","volume":"10","year":"1995","journal-title":"Hum Psychopharmacol"},{"key":"bib91-20230816","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130050731","article-title":"A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder","volume":"139","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"bib92-20230816","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.4088\/JCP.v63n1112","article-title":"Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study","volume":"63","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"bib93-20230816","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ppc.12012","article-title":"Biological perspectives: hydroxyzine for anxiety: another look at an old drug","volume":"49","year":"2013","journal-title":"Perspect Psychiatr Care"},{"key":"bib94-20230816","first-page":"CD006815","article-title":"Hydroxyzine for generalised anxiety disorder","volume":"12","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"bib95-20230816","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","year":"2014","journal-title":"J Psychopharmacol"},{"key":"bib96-20230816","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2007-984400","article-title":"Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials","volume":"40","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"bib97-20230816","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1461145709990460","article-title":"Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder","volume":"13","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"bib98-20230816","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1345\/aph.1Q405","article-title":"Pregabalin for the treatment of generalized anxiety disorder","volume":"46","year":"2012","journal-title":"Ann Pharmacother"},{"key":"bib99-20230816","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12630-013-9890-1","article-title":"Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial","volume":"60","year":"2013","journal-title":"Can J Anaesth"},{"key":"bib100-20230816","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4088\/JCP.10r06218blu","article-title":"The pharmacologic treatment of anxiety disorders: a review of progress","volume":"71","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"bib101-20230816","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000321079","article-title":"Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data","volume":"80","year":"2011","journal-title":"Psychother Psychosom"},{"key":"bib102-20230816","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.v66n0510","article-title":"Why isn\u2019t bupropion the most frequently prescribed antidepressant?","volume":"66","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"bib103-20230816","first-page":"46","article-title":"A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder","volume":"41","year":"2008","journal-title":"Psychopharmacol Bull"},{"key":"bib104-20230816","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4088\/JCP.v62n1005","article-title":"Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?","volume":"62","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bib105-20230816","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4088\/JCP.v59n0705","article-title":"A prospective safety surveillance study for bupropion sustained-release in the treatment of depression","volume":"59","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"bib106-20230816","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YIC.0b013e3283457d73","article-title":"Augmentative quetiapine in partial\/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study","volume":"26","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"bib107-20230816","first-page":"E7","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study","volume":"25","year":"2013","journal-title":"Ann Clin Psychiatry"},{"key":"bib108-20230816","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00213-008-1087-x","article-title":"Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings","volume":"197","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"bib109-20230816","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4088\/JCP.v66n1016","article-title":"Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"66","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"bib110-20230816","first-page":"41","article-title":"Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial","volume":"40","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"bib111-20230816","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","year":"2006","journal-title":"Biol Psychiatry"},{"key":"bib112-20230816","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"bib113-20230816","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/JCP.0000000000000118","article-title":"Quetiapine treatment in youth is associated with decreased insulin secretion","volume":"34","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"bib114-20230816","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment","volume":"27","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"bib115-20230816","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2013.12101353","article-title":"A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder","volume":"171","year":"2014","journal-title":"Am J Psychiatry"},{"key":"bib116-20230816","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"bib117-20230816","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","year":"2000","journal-title":"Am J Psychiatry"},{"key":"bib118-20230816","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","year":"2008","journal-title":"Depress Anxiety"},{"key":"bib119-20230816","doi-asserted-by":"crossref","first-page":"g1888","DOI":"10.1136\/bmj.g1888","article-title":"Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies","volume":"348","year":"2014","journal-title":"BMJ"},{"key":"bib120-20230816","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"bib121-20230816","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study","volume":"73","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"bib122-20230816","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-135-1-200107030-00036","article-title":"Kava hepatotoxicity","volume":"135","year":"2001","journal-title":"Ann Intern Med"},{"key":"bib123-20230816","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","year":"2005","journal-title":"Am J Psychiatry"},{"key":"bib124-20230816","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1461145714000017","article-title":"Lavender oil preparation Silexan is effective in generalized anxiety disorder\u2014a randomized, double-blind comparison to placebo and paroxetine","volume":"17","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"bib125-20230816","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/YIC.0b013e32833e34d9","article-title":"Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial","volume":"26","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"bib126-20230816","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/YIC.0b013e32834d9f49","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study","volume":"27","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"bib127-20230816","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JCP.0b013e3181d21951","article-title":"Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study","volume":"30","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"bib128-20230816","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.jcp.0000177853.15910.de","article-title":"Open-label pilot study of ziprasidone for refractory generalized anxiety disorder","volume":"25","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"bib129-20230816","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4088\/JCP.12m08297","article-title":"A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder","volume":"75","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"bib130-20230816","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","article-title":"Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review","volume":"67","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"bib131-20230816","first-page":"113","article-title":"The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study","volume":"162","year":"2011","journal-title":"Clin Ter"},{"key":"bib132-20230816","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.v67n0307","article-title":"An open-label trial of risperidone augmentation for refractory anxiety disorders","volume":"67","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"bib133-20230816","first-page":"207","article-title":"An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder","volume":"27","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"bib134-20230816","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1017\/S109285290001676X","article-title":"Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder","volume":"13","year":"2008","journal-title":"CNS Spectr"},{"key":"bib135-20230816","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/13651501.2012.722645","article-title":"The best next drug in the course of generalized anxiety disorders: the \u201cPN-GAD-algorithm.\u201d","volume":"17","year":"2013","journal-title":"Int J Psychiatry Clin Pract"},{"key":"bib137-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10177833.2013.11790811","article-title":"On the value of evidence-based psychopharmacology algorithms","volume":"23","year":"2013","journal-title":"Bull Clin Psychopharmacol"},{"key":"bib138-20230816","first-page":"98","article-title":"Doctors wielding data","volume":"94","year":"2005","journal-title":"Bus Week"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00023727-201607000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T22:11:47Z","timestamp":1692223907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-201607000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/hrp.0000000000000098","relation":{},"ISSN":["1465-7309","1067-3229"],"issn-type":[{"value":"1465-7309","type":"electronic"},{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}